Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Rituximab 70Cyclophosphamide 46fludarabine 21fludarabine phosphate 20Mycophenolic Acid 20Etoposide 18Whole-Body Irradiation 17Filgrastim 15Radiotherapy 14Antilymphocyte Serum 14Tacrolimus 13Melphalan 13Gemcitabine 13Cyclosporine 13Busulfan 13Methotrexate 12Lenalidomide 12Bortezomib 12Bendamustine Hydrochloride 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10Cytarabine 10Doxorubicin 8Dexamethasone 8venetoclax 7thymoglobulin 7pembrolizumab 7Thiotepa 7Methylprednisolone 7Granulocyte Colony-Stimulating Factor 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Non-Hodgkin × TNFSF10 protein, human × Clear all
NCT00400764 2011-11-23

A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas

Genentech, Inc.

Phase 1/2 Terminated
72 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡